ANCA-associated vasculitis trials in China

In China 38 Also abroad 97

38 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in China
MYTP01 for Immune-Mediated Diseases
Where
Hangzhou
Age
18 years to 65 years
People
160
Run by
Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764
No phaseTaking people
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Where
Shanghai
Age
18 years to 65 years
People
6
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646
Phase 1Taking people
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
12
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647
Phase 1Taking people
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Where
Hefei
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721
Phase 1Taking people
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Where
Tianjin
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07123519
Early phase 1Taking people
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 80 years
People
10
Run by
Peking University Third Hospital
See details and how to joinNCT07301164
Phase 1/2Taking people
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 80 years
People
9
Run by
Peking University Third Hospital
See details and how to joinNCT06828042
Phase 2Taking people
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
Where
Beijing
Age
18 years and over
People
20
Run by
Chinese PLA General Hospital
See details and how to joinNCT07746180
Early phase 1Not yet taking people in China
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Where
Shanghai
Age
18 years to 75 years
People
30
Run by
Grit Biotechnology
See details and how to joinNCT07389499
Phase 3Taking people
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Where
Beijing, Cangzhou, Changchun, Changde, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hohhot, Huaihua, Jinan, Kunming, Lanzhou, Lishui, Liuzhou, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shaoguan, Shengyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tangshan, Ürümqi, Weifang, Wuhan, Xiamen, Xi'an, Xi’an, Xuzhou, Yanbian, Yichang, Zhengzhou, Zhuzhou
Age
18 years to 75 years
People
300
Run by
Staidson (Beijing) Biopharmaceuticals Co., Ltd
See details and how to joinNCT07168161
Early phase 1Taking people
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Where
Shanghai
Age
18 years to 75 years
People
96
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07203404
Early phase 1Not yet taking people in China
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680
Phase 1Taking people
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Where
Nanjing
Age
18 years to 65 years
People
24
Run by
Nanjing University School of Medicine
See details and how to joinNCT06285279
Early phase 1Taking people
MTS109 in Patients With Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
15
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07526350
Early phase 1Taking people
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07507201
Early phase 1Taking people
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Where
Bengbu
Age
18 years to 70 years
People
20
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06548607
Phase 1Taking people
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Where
Bengbu
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762
Phase 1Taking people
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Where
Xuzhou
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801
Phase 1Not yet taking people in China
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Where
Shanghai
Age
5 years to 18 years
People
12
Run by
Children's Hospital of Fudan University
See details and how to joinNCT07439029
Early phase 1Taking people
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
60
Run by
Changhai Hospital
See details and how to joinNCT07246096
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07305116
Early phase 1Taking people
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Where
Lianyungang
Age
18 years to 70 years
People
18
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06775912
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087
No phaseTaking people
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Where
Hangzhou
Age
18 years to 65 years
People
15
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270
No phaseNot yet taking people in China
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Where
Tianjin
Age
18 years to 65 years
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322